Contrast Media Injectors - Market Insights, Competitive Landscape, and Market Forecast-2028

The market is expected to advance at a respectable CAGR forecast till 2028 owing to the rising prevalence of chronic diseases across the globe and surging demand of minimally invasive surgeries.

The global contrast media injectors market was valued at USD 1,172 million in 2022 and is likely to register a CAGR of 4.27% during the forecast period from 2023 to 2028 to reach USD 1,504 million by 2028. The contrast media injectors market is observing significant market growth primarily owing to the mounting figures of various chronic diseases such as cancers, neurological, and cardiovascular among others. Further, an increase in the geriatric population base prone to chronic diseases, surging unhealthy and sedentary lifestyles among youngsters, increasing demand for minimally invasive surgeries, technological advancements such as syringeless injectors and dose recording systems, increasing product launches and approvals, surging investments by key players, and others will also affect the demand for contrast media injectors positively during the forecast period. Therefore, the market of contrast media injectors is estimated to grow at a substantial CAGR during the forecast period from 2023 to 2028.

Contrast Media Injectors Market Dynamics:

According to World Health Organization (WHO) 2022 factsheet, the new cases of breast cancer in 2020 was 2.26 million, followed by lung cancer with 2.21 million cases, colon and rectum cancer reported 1.93 million new cases, prostate cancer with 1.41 million cases, skin cancer - with 1.20 million cases, and stomach cancer with 1.09 million cases, worldwide. Contrast media injectors are used to inject contrast media into cancer patients for proper visualization of normal and pathologic anatomy of tumor.

In case of cancers, new abnormal blood vessels may develop, which tend to be leakier than normal capillaries. In this case, if the contrast media is injected using injectors for diagnosis then the lesion can be much more visible on contrast enhanced scaners as compared to the other diagnosis method. Thus, the increasing prevalence of cancer will ultimately increase the demand for contrast media injectors.

Cardiovascular diseases are considered to be the leading cause of death globally. As per the WHO 2021 data, an estimated 17.9 million people died from cardiovascular disorders in 2019, illustrating 32% of all global deaths. Out of the 17 million premature deaths (under the age of 70 years) due to non-communicable diseases in 2019, 38% of the deaths were caused due to cardiovascular disorders. The increasing mortality can be reduced if proper diagnosis of cardiovascular diseases is done at an apt time using imaging devices. During imaging diagnosis contrast media is injected with the help of contrast media injectors to get proper visualization of the anatomy. Thus, affecting the demand for contrast media injectors during the forecast period.

Further, several advances in contrast media injector technology have been made to reduce contrast media waste and automate data collection about a patient's dose. Automated injector systems, for example, precisely collect the amount of contrast media used. Vendors provide personalized doses to patients by utilizing data from EMR or Picture Archiving and Communication System (PACS). Syringeless injectors are one such advancement in reducing contrast media waste. Also, most of the manufacturers are working on new products to reduce contrast media waste and gain a competitive advantage. For instance, Bracco's smart syringeless injectors that use every drop of contrast loaded into the system for maximum efficiency. Smart injectors record the amount injected as well as the imaging protocol used and transmit the data to the PACS. In contrast to media injector technology, these constant technological advancements are expected to boost the market during the forecast period. Therefore, the factors stated above collectively will drive the overall contrast media injectors market during the forecast period from 2023-2028.

However, the high cost of contrast media injectors and consumables, adverse effects of contrast agents, and others may prove to be challenging factors for contrast media injectors' market growth.

The contrast media injectors market was significantly impacted during the period of COVID- 19 pandemic as the volume of imaging cases in many radiology departments dropped dramatically. The COVID-19 outbreak impacted patients' access to healthcare facilities as the pandemic forced them to wait for lifesaving imaging procedures. Moreover, the demand for contrast media injectors suffered a disgrace owing to the imposition of strict lockdown rules, and disruption in manufacturing, supply chain, and workforce. However, with the ease of lockdown restrictions, the upturn of resources and supply chain, the administration of a vaccine to the public, and the return of patients to hospitals or diagnostic imaging centers, the demand for contrast media injectors increased and is driving the market growth.

Contrast Media Injectors Market Segment Analysis:

Contrast Media Injectors Market by Product (Injector Systems [CT Injector Systems, MRI Injector Systems, and Cardiovascular/Angiography Injector Systems] and Consumables [Tubing, Syringe, and Other]), Type of Injectors (Single-Head Injectors, Dual-Head Injectors, and Syringeless Injectors), Application (Radiology, Interventional Cardiology, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the product segment of the contrast media injectors market, the CT Injector Systems segment is expected to have a significant revenue share in the year 2022. This is owing to its widespread use in the detection and treatment of vascular disease, cancer, and orthopedic injuries and disorders. Moreover, technological advancements and the launch of new products are further expected to propel the growth of the segment.

CT injectors are expected to grow in popularity as the use of CT systems has increased. During imaging, these CT systems employ a dual-head injector with two syringes for initial and follow-up contrast doses. Major academic institutions and pharmaceutical companies have been engaged in continuous R&D to develop protocols that assist CT users with the advanced capabilities of newer imaging systems.

Furthermore, major players are gradually implementing various strategies, such as collaborative initiatives to remain competitive in the market. For instance, in September 2019, The MedradStellant Flex CT injectable system from Bayer was released. The Stellant Flex system is a user-driven system with little technician training and automation. It provides personalized patient protocols and personalized imaging, as well as flexible capital equipment alternatives through the company's TechCare service.

Also, in May 2022, Bayer Korea started marketing MEDRAD Centargo, a computed tomography (CT) injection medical device, which received approval from the Ministry of Food and Drug Safety in January. Similarly, Ulrich Medical, a German medical technology company, presented a version of its CT motion contrast media injector designed for the American market at the RSNA in Chicago in May 2020. It was approved by the FDA and marketed in collaboration with GE Healthcare.

Therefore, owing to the above-mentioned factors, the demand for CT injector systems surges, thereby the category is expected to witness considerable growth eventually contributing to the overall growth of the global contrast media injectors market during the forecast period.

North America Is Expected To Dominate The Overall Contrast Media Injectors Market:

Among all the regions, North America is expected to dominate global contrast media injectors in the year 2022 and is expected to do the same during the forecast period from 2023-2028.

This can be ascribed to the rising demand for minimally invasive surgeries in the region as the minimally invasive surgical procedures with contrast media injectors deliver high-quality real-time imaging of the surgical site, and ensure that surgeons are treating the appropriate area. Further, the increasing burden of chronic diseases, presence of contrast media injectors manufacturer's hub in the US, rising product launches and approvals, favorable reimbursement scenarios, and others act as supportive factors for the North America contrast media injectors market growth.

For instance, as per the data provided by the American Cancer Society, it is estimated that in 2023, nearly 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States.

According to the CDC data updated in 2021, chronic diseases such as heart disease, cancer, and diabetes are the leading causes of death and disability in the United States. They also contribute to USD 3.8 trillion in annual healthcare costs. Six in 10 adults in the country have a chronic disease, and four in every 10 have two or more chronic diseases. Additionally, according to Heart Disease & Stroke Statistical Fact Sheet 2020, a minimum of 40,000 infants are expected to be affected yearly by congenital heart defects in the United States. About 25% or 2.4 (per 1,000 live births) require treatment in the first year of an infant's life.

Thus, the increasing prevalence of various chronic diseases will increase the demand for contrast media injectors as these injectors are usually employed during the diagnosis of the above-mentioned diseases. Therefore, the increasing prevalence of chronic diseases will propel the market of contrast media injectors during the forecast period.

Additionally, countries such as the U.S. and Canada have seen an increase in hospital admissions in recent years, as a result of the high occurrence of chronic medical diseases & fatal injuries.

The surging product launches and approvals in the region will in turn propel the overall market. For instance, in July 2021, Ulrich received FDA approval for the ulrichINJECT CT motion. The ulrichINJECT CT motion system consists of the CT motion terminal, CT motion injector, and CT motion tubing system. Also, in November 2022, GE Healthcare and Ulrich Medical announced an agreement to offer a branded multi-dose contrast media injector in the United States.

Therefore, the interplay of the aforementioned factors above would provide a conducive growth environment for the North America region in the contrast media injectors market.

Contrast Media Injectors Market Key Players:

Some of the key market players operating in the contrast media injectors market include GE HealthCare, Bracco, MEDTRON AG, Ulrich GmbH & Co. KG, Bayer Pharmaceuticals, Nemoto Kyorindo co., Ltd., SINO MDT, APOLLO RT Co. Ltd., Shenzhen Seacrown Electromechanical Co., Ltd., HONG KONG MEDI CO LIMITED, and others.

Recent Developmental Activities in the Contrast Media Injectors Market:

• In December 2021, Guerbet and Bracco Imaging announced a global collaboration for Gadopiclenol, a next-generation magnetic resonance imaging (MRI) contrast agent.
• In December 2021, Qaelum NV announced a strategic partnership with Ulrich GmbH & Co. KG in Ulm to combine their advanced Contrast Management solution with Ulrich Medical's contrast media injectors to support the needs of hospitals and imaging networks.

Key Takeaways from the Contrast Media Injectors Market Report Study

• Market size analysis for current contrast media injectors market size (2022), and market forecast for 5 years (2023-2028)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the contrast media injectors market.
• Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the global contrast media injectors market.
• Various opportunities are available for the other competitor in the contrast media injector's market space.
• What are the top-performing segments in 2022? How these segments will perform in 2028?
• Which are the top-performing regions and countries in the current contrast media injector's market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for contrast media injector's market growth in the coming future?

Target Audience who can be benefited from this Contrast Media Injectors Market Report Study

• Contrast media injectors products providers
• Research organizations and consulting companies
• Contrast media injectors- related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing, in contrast media injectors
• Various end users who want to know more about the contrast media injectors market and the latest technological developments in the contrast media injectors market.

Frequently Asked Questions for the Contrast Media Injectors Market:

1. What are contrast media injectors?

Contrast media injectors (CMI) are devices employed for injecting contrast media into the body to improve the visibility of tissues for medical imaging procedures.

2. What is the global market for contrast media injectors?

The global contrast media injectors market was valued at USD 1,172 million in 2022 and is likely to register a CAGR of 4.27% during the forecast period from 2023 to 2028 to reach USD 1,504 million by 2028.

3. What are the drivers for the global contrast media injectors market?

The contrast media injectors market is witnessing positive market growth owing to the factors such as the increasing demand for minimally invasive surgeries, rising prevalence of chronic disorders, technological advancements and an increasing number of regulatory approvals, increasing product launches and approvals, and others will create an exigency for the contrast media injectors market.

4. Who are the key players operating in the global contrast media injectors market?

Some of the key market players operating in the contrast media injectors market include GE HealthCare, Bracco, MEDTRON AG, Ulrich GmbH & Co. KG, Bayer Pharmaceuticals, Nemoto Kyorindo co., Ltd., SINO MDT, APOLLO RT Co. Ltd., Shenzhen Seacrown Electromechanical Co., Ltd., HONG KONG MEDI CO LIMITED, and others.

5. Which region has the highest share of the contrast media injectors market?

Among all the regions, North America is estimated to amass a significant revenue share in the global contrast media injectors market. This can be ascribed to the rising demand for minimally invasive surgeries, increasing burden of chronic diseases, presence of contrast media injectors manufacturer's hub in the US, rising product launches and approvals, and others act as a supportive factor for the North American contrast media injectors market growth.


This product will be delivered within 3-5 business days.